ResMed Inc. filed a Form 8-K on October 29, 2026, reporting its quarterly operating results for the period ended September 30, 2026, and announcing a quarterly cash dividend of US $0.66 per share declared by its board of directors.

Key Highlights

  • Quarterly dividend declared: The board of directors declared a cash dividend of US $0.66 per share on common stock.
  • Record date: November 12, 2026, with payment scheduled for December 17, 2026.
  • Ex-dividend date: November 11, 2026, applies to both common stockholders and CDI holders.
  • CDI holders: Holders of CHESS Depositary Interests trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, reflecting the 10:1 ratio between CDIs and NYSE shares, based on the exchange rate on the record date.
  • Quarterly results disclosed: A press release describing results of operations for the quarter ended September 30, 2026, was furnished as Exhibit 99.1.
  • ASX waiver obtained: ResMed received a waiver from the ASX settlement operating rules to defer processing conversions between its common stock and CDI registers from November 11 through November 12, 2026, inclusive.

ResMed's Q1 FY2027 Earnings Release and Dividend Announcement Details

ResMed Inc. (NYSE:RMD), headquartered at 9001 Spectrum Center Blvd., San Diego, California, filed the 8-K with the SEC on October 29, 2026, under Items 2.02 and 8.01. Under Item 2.02, the company disclosed that it issued a press release, furnished as Exhibit 99.1, describing results of operations for the quarter ended September 30, 2026. According to the filing, the information furnished under Item 2.02 and the attached exhibit is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.

Under Item 8.01, the filing disclosed that ResMed's board of directors declared a quarterly cash dividend of US $0.66 per share, payable to holders of common stock trading on the New York Stock Exchange. The record date is November 12, 2026, and the payment date is December 17, 2026. The ex-dividend date is November 11, 2026, for both common stockholders and CDI holders.

For holders of CHESS Depositary Interests trading on the Australian Securities Exchange, the filing stated the dividend will be paid in Australian currency, converted at the exchange rate on the record date and reflecting the 10:1 ratio between CDIs and NYSE shares. The filing also noted that ResMed received a waiver from the ASX's settlement operating rules, allowing the company to defer processing conversions between its common stock and CDI registers from November 11 through November 12, 2026, inclusive. The report was signed by Aaron Bloomer, Chief Financial Officer.

What Was Disclosed

ResMed's 8-K filed October 29, 2026, covers two items: the furnishing of a quarterly earnings press release for the period ended September 30, 2026, and the declaration of a US $0.66 per share quarterly cash dividend with a December 17, 2026, payment date.